Shotaro Tatekawa

Dr. Shotaro Tatekawa

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2022 in Cancers
Verified
Journal Article
Open access
PDF file
JYJunya Yamamoto
Junya Yamamoto
YTYutaka Takahashi
Yutaka Takahashi
KMKazumasa Minami
Kazumasa Minami
KTKeisuke Tamari
Keisuke Tamari
SKShohei Katsuki
Shohei Katsuki
MKMasahiko Koizumi
Masahiko Koizumi
Pancreatic cancer is an extremely treatment-resistant neoplasm to chemotherapy and immunotherapy. The combination of photon beam irradiation and anti-CTLA-4 antibody (C4) for the anti-tumor effect enhancement at local and distant tumors (abscopal tumors) was investigated using the pancreatic ductal adenocarcinoma (PDAC) mouse model. Pan02 cells were bilaterally inoculated to both legs of C57BL/6 mice. High dose photon beams in a hypofractionation or a single fraction were delivered to the tumors on one leg. Monotherapy with C4 via i.p. was not effective for PDAC. The high dose irradiation to the local tumors produced significant shrinkage of irradiated tumors but did not induce the abscopal responses. In contrast, the combination therapy of high dose photon beam irradiation in both hypofractionation and a single fraction with C4 enhanced the anti-tumor effect for abscopal tumors with significantly prolonged overall survival. The flow cytometric analysis revealed that the combination therapy dramatically decreased the regulatory T cell (Treg) proportion while increasing the cytotoxic T lymphocytes in both local and abscopal tumors. These results suggest that high dose photon beam irradiation plays an important role in C4 therapy to enhance the abscopal response with immune microenvironment changes in PDAC, regardless of the fractionation in radiation therapy.

12 October 2021 in Cancers
Verified
Journal Article
Open access
PDF file
STShotaro Tatekawa
Shotaro Tatekawa
KOKen Ofusa
Ken Ofusa
RCRyota Chijimatsu
Ryota Chijimatsu
AVAndrea Vecchione
Andrea Vecchione
KTKeisuke Tamari
Keisuke Tamari
HIHideshi Ishii
Hideshi Ishii
As cancer is a genetic disease, methylation defines a biologically malignant phenotype of cancer in the association of one-carbon metabolism-dependent S-adenosylmethionine (SAM) as a methyl donor in each cell. Methylated substances are involved in intracellular metabolism, but via intercellular communication, some of these can also be secreted to affect other substances. Although metabolic analysis at the single-cell level remains challenging, studying the “methylosystem” (i.e., the intercellular and intracellular communications of upstream regulatory factors and/or downstream effectors that affect the epigenetic mechanism involving the transfer of a methyl group from SAM onto the specific positions of nucleotides or other metabolites in the tumor microenvironment) and tracking these metabolic products are important research tasks for understanding spatial heterogeneity. Here, we discuss and highlight the involvement of RNA and nicotinamide, recently emerged targets, in SAM-producing one-carbon metabolism in cancer cells, cancer-associated fibroblasts, and immune cells. Their significance and implications will contribute to the discovery of efficient methods for the diagnosis of and therapeutic approaches to human cancer.

6 January 2021 in Acta Oncologica
Verified
Journal Article
Closed access
STShotaro Tatekawa
Shotaro Tatekawa
SSShigetoshi Shimamoto
Shigetoshi Shimamoto
YMYoshiaki Miyata
Yoshiaki Miyata
YYYutaro Yoshino
Yutaro Yoshino
THTakero Hirata
Takero Hirata
KOKazuhiko Ogawa
Kazuhiko Ogawa
Previous studies reported that cigarette smoking during radiation therapy was associated with unfavorable outcomes in various cancers using medical interviewing or monitoring of cotinine. Here, we ...

4 January 2022 in International Journal of Radiation Biology
Verified
Journal Article
Closed access
YSYuji Seo
Yuji Seo
KTKeisuke Tamari
Keisuke Tamari
YTYutaka Takahashi
Yutaka Takahashi
KMKazumasa Minami
Kazumasa Minami
STShotaro Tatekawa
Shotaro Tatekawa
KOKazuhiko Ogawa
Kazuhiko Ogawa
Poly (ADP-ribose) polymerase inhibitors (PARPi) are known to induce radiosensitization. However, the exact mechanisms of radiosensitization remain unclear. We previously reported that PARPi may hav...

15 August 2023 in Advances in Radiation Oncology
Verified
Journal Article
Open access
KTKeisuke Tamari
Keisuke Tamari
KMKazumasa Minami
Kazumasa Minami
STShotaro Tatekawa
Shotaro Tatekawa
YSYuji Seo
Yuji Seo
TFTakahito Fukusumi
Takahito Fukusumi
KOKazuhiko Ogawa
Kazuhiko Ogawa
Radiation therapy is widely used to treat head and neck squamous cell carcinoma (HNSCC). This study evaluated the association between circulating plasma programmed death-ligand 1 (PD-L1) and the outcomes of patients with HNSCC after radiation therapy. In this retrospective observational study, plasma samples of 76 patients with HNSCC who underwent radiation therapy from June 2019 to August 2021 were analyzed. These plasma samples were obtained before radiation therapy. The median follow-up was 32.5 months. Total and exosomal PD-L1 was measured by enzyme-linked immunosorbent assay and retrospectively analyzed for association with overall survival (OS), progression-free survival (PFS), and local control (LC). Prognostic factors among patients' characteristics and circulating PD-L1 in plasma were evaluated by univariate (log-rank test) and multivariate (Cox proportional hazards model) analyses. The median concentration of total PD-L1 in plasma was 115.1 pg/mL (95% CI, 114.7-137.9 pg/mL), and the median concentration of exosomal PD-L1 was 2.8 pg/mL (95% CI, 6.0-13.0 pg/mL). Univariate and multivariate analyses showed exosomal PD-L1 as a prognostic factor for PFS and LC. Patients with high exosomal PD-L1 in plasma had poor PFS and LC compared with those with low exosomal PD-L1, indicating that 1-year PFS was 79.2% versus 33.3% (P < .001) and 1-year LC was 87.3% versus 50.0% (P < .001) in patients with high and low exosomal PD-L1, respectively. However, exosomal PD-L1 in plasma had no significant effect on OS. Total PD-L1 in plasma did not correlate with PFS, LC, and OS. The pretreatment circulating exosomal PD-L1 in plasma of patients with HNSCC was a prognostic factor after radiation therapy.

14 August 2022 in Advances in Radiation Oncology
Verified
Journal Article
Open access
STShotaro Tatekawa
Shotaro Tatekawa
SHShigenori Hoshino
Shigenori Hoshino
NTNorihiko Takemoto
Norihiko Takemoto
MOMichio Oda
Michio Oda
YAYuichi Akino
Yuichi Akino
KOKazuhiko Ogawa
Kazuhiko Ogawa
The radiation recall phenomenon (RRP) is a rare and unexpected late complication of radiation therapy (RT). Although predominantly in the skin, RRP of the upper respiratory tract has also been reported. In general, RRP is caused by anticancer agents, and the COVID-19 vaccine has also been reported to cause RRP in recent years. A 50-year-old woman who had received RT around the larynx 3 years prior and was receiving a docetaxel + ramucirumab (RAM) regimen experienced recurrent sore throat. The administration of RAM was discontinued after a gastroscopic examination revealed mucosal bleeding from around the larynx, which was thought to be RRP caused by RAM, a vascular endothelial growth factor inhibitor. After the remission of the RRP, the patient received a COVID-19 vaccine (Pfizer-BioNTech). Five days later, the appearance of cough and recurrence of sore throat worsened with time, and marked stridor was observed. The patient was admitted, and steroid pulse therapy was administered for 3 days starting on day 18 after vaccination. On day 50 after vaccination, edema of the vocal cords improved. When administering COVID-19 vaccines, considering that these vaccines may cause RRP is important, because RRP can be fatal in patients with a history of RT in the laryngeal region and treated with vascular endothelial growth factor inhibitors.